DaVita (NYSE:DVA) Sets New 52-Week Low – What’s Next?

DaVita Inc. (NYSE:DVA) shares reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $107.01 and last traded at $107.70, with a volume of 174566 shares trading hands. The stock had previously closed at $110.10.

Wall Street Analyst Weigh In

Several brokerages have issued reports on DVA. Weiss Ratings reaffirmed a “hold (c)” rating on shares of DaVita in a report on Monday, December 29th. TD Cowen dropped their price objective on shares of DaVita from $154.00 to $133.00 and set a “hold” rating on the stock in a research report on Monday, November 3rd. Zacks Research raised shares of DaVita from a “strong sell” rating to a “hold” rating in a report on Friday, November 28th. Cowen reiterated a “hold” rating on shares of DaVita in a research note on Monday, November 3rd. Finally, UBS Group reissued a “buy” rating on shares of DaVita in a report on Monday, December 15th. One analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $145.60.

DaVita Trading Down 3.9%

The firm has a market cap of $7.47 billion, a price-to-earnings ratio of 10.89, a PEG ratio of 0.69 and a beta of 0.99. The firm’s 50 day simple moving average is $117.49 and its two-hundred day simple moving average is $128.68.

DaVita (NYSE:DVA) last announced its earnings results on Wednesday, October 29th. The company reported $2.51 EPS for the quarter, missing the consensus estimate of $3.17 by ($0.66). The business had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.43 billion. DaVita had a negative return on equity of 13,370.89% and a net margin of 5.80%.The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the prior year, the business posted $2.59 earnings per share. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. As a group, equities research analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DaVita

A number of large investors have recently modified their holdings of DVA. Invesco Ltd. increased its stake in shares of DaVita by 2.0% in the 3rd quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock valued at $223,122,000 after purchasing an additional 32,358 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in DaVita by 8.8% in the third quarter. Dimensional Fund Advisors LP now owns 1,085,593 shares of the company’s stock valued at $144,230,000 after buying an additional 88,061 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in DaVita by 109.7% in the third quarter. Arrowstreet Capital Limited Partnership now owns 553,809 shares of the company’s stock valued at $73,585,000 after acquiring an additional 289,725 shares during the last quarter. Neuberger Berman Group LLC grew its position in DaVita by 138.5% in the third quarter. Neuberger Berman Group LLC now owns 463,250 shares of the company’s stock valued at $61,502,000 after acquiring an additional 269,015 shares during the last quarter. Finally, KBC Group NV raised its stake in DaVita by 38.7% during the second quarter. KBC Group NV now owns 374,749 shares of the company’s stock worth $53,383,000 after acquiring an additional 104,554 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.